A First-in-Human Clinical Trial of Pharmacologic Ascorbate and Ferumoxytol Combined With Concomitant Temozolomide and External Beam Radiation Therapy for Newly Diagnosed Glioblastoma
Latest Information Update: 16 Jul 2024
At a glance
- Drugs Ascorbic acid (Primary) ; Ferumoxytol (Primary) ; Temozolomide (Primary)
- Indications Diffuse intrinsic pontine glioma; Glioblastoma
- Focus Adverse reactions; First in man
- Acronyms XACT-Fe-GBM-01
- 03 Jul 2024 Planned End Date changed from 31 Dec 2025 to 31 Dec 2026.
- 03 Jul 2024 Planned primary completion date changed from 30 Jun 2024 to 30 Jun 2025.
- 03 Jul 2024 Status changed from active, no longer recruiting to recruiting.